APM
MRVI icon

Avidity Partners Management’s Maravai LifeSciences MRVI Stock Holding History

Avidity Partners Management’s Portfolio MRVI Stock Details MRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-2,963,545
Closed -$124M – 122
2021
Q2 		$124M Buy
2,963,545
+202,000
+7% +$7.83M 3.34% 5
2021
Q1 		$98.4M Sell
2,761,545
-684,227
-20% -$22.7M 2.72% 7
2020
Q4 		$96.7M Buy
+3,445,772
New +$96M 3.14% 6

Other funds holding MRVI

GTCR LLC
GTCR LLC Chicago, Illinois $3.91B AUM 14.64% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Select Equity Group
Select Equity Group New York $20.2B AUM 17.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
CIP
Champlain Investment Partners Burlington, Vermont $3.89B AUM 16.15% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Avidity Partners Management's MRVI Position: Q3 2021 in Review

Avidity Partners Management sold out of Maravai LifeSciences (MRVI) in Q3 2021, closing a stake of 2,963,545 shares — an estimated $124M sold.

Avidity Partners Management first reported a position in MRVI in Q4 2020 and held it in 3 quarters. The position peaked at $124M in Q2 2021. 228 funds tracked by Wall St. Rank hold MRVI as of Q3 2021.

  • Avidity Partners Management reported no remaining Maravai LifeSciences position as of Q3 2021 after selling out during the quarter.
  • Avidity Partners Management sold 2,963,545 Maravai LifeSciences shares in Q3 2021, an estimated $124M.
  • Avidity Partners Management first reported a position in Maravai LifeSciences in Q4 2020 and held it in 3 quarters.
  • Avidity Partners Management's Maravai LifeSciences position peaked at $124M in Q2 2021.
  • 228 funds tracked by Wall St. Rank held Maravai LifeSciences as of Q3 2021.

Based on Avidity Partners Management's 13F filing for Q3 2021, filed 15 Nov 2021.